Nova Mentis Life Science Corp. (NOVA.CN)
CAD 0.01
(-50.0%)
CAD 0.01
(-50.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 31.05 Thousand CAD | -89.53% |
| 2022 | 296.78 Thousand CAD | -66.32% |
| 2021 | 881.15 Thousand CAD | -82.7% |
| 2020 | 5.09 Million CAD | -22.67% |
| 2019 | 6.58 Million CAD | -12.79% |
| 2018 | 7.55 Million CAD | 134.14% |
| 2017 | 3.22 Million CAD | 341.8% |
| 2016 | 729.94 Thousand CAD | 140.51% |
| 2015 | 303.5 Thousand CAD | 10.57% |
| 2014 | 274.49 Thousand CAD | -82.81% |
| 2013 | 1.59 Million CAD | -5.58% |
| 2012 | 1.69 Million CAD | -78.72% |
| 2011 | 7.94 Million CAD | 168.62% |
| 2010 | 2.95 Million CAD | -29.42% |
| 2009 | 4.19 Million CAD | 118.75% |
| 2008 | 1.91 Million CAD | 18.68% |
| 2007 | 1.61 Million CAD | 136.48% |
| 2006 | 682.95 Thousand CAD | 323.29% |
| 2005 | 161.34 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 40.09 Thousand CAD | 29.1% |
| 2024 Q2 | 26.34 Thousand CAD | -34.29% |
| 2023 Q3 | 53.88 Thousand CAD | -12.35% |
| 2023 Q1 | 229.26 Thousand CAD | -22.75% |
| 2023 Q2 | 61.47 Thousand CAD | -73.19% |
| 2023 FY | 31.05 Thousand CAD | -89.53% |
| 2023 Q4 | 31.05 Thousand CAD | -42.36% |
| 2022 FY | 296.78 Thousand CAD | -66.32% |
| 2022 Q2 | 1.36 Million CAD | -25.68% |
| 2022 Q4 | 296.78 Thousand CAD | -74.4% |
| 2022 Q1 | 1.83 Million CAD | 108.21% |
| 2022 Q3 | 1.15 Million CAD | -14.96% |
| 2021 FY | 881.15 Thousand CAD | -82.7% |
| 2021 Q4 | 881.15 Thousand CAD | -73.99% |
| 2021 Q3 | 3.38 Million CAD | -15.02% |
| 2021 Q2 | 3.98 Million CAD | -8.64% |
| 2021 Q1 | 4.36 Million CAD | -14.29% |
| 2020 Q1 | 6.34 Million CAD | -3.61% |
| 2020 FY | 5.09 Million CAD | -22.67% |
| 2020 Q2 | 7.38 Million CAD | 16.39% |
| 2020 Q3 | 7.17 Million CAD | -2.87% |
| 2020 Q4 | 5.09 Million CAD | -29.04% |
| 2019 Q4 | 6.58 Million CAD | -3.78% |
| 2019 Q1 | 7.27 Million CAD | -3.66% |
| 2019 FY | 6.58 Million CAD | -12.79% |
| 2019 Q2 | 6.97 Million CAD | -4.13% |
| 2019 Q3 | 6.84 Million CAD | -1.86% |
| 2018 Q4 | 7.55 Million CAD | -1.68% |
| 2018 FY | 7.55 Million CAD | 134.14% |
| 2018 Q1 | 7.68 Million CAD | 138.35% |
| 2018 Q2 | 7.54 Million CAD | -1.87% |
| 2018 Q3 | 7.67 Million CAD | 1.82% |
| 2017 Q1 | 1 Million CAD | 37.03% |
| 2017 Q4 | 3.22 Million CAD | 298.97% |
| 2017 Q3 | 808.31 Thousand CAD | -18.37% |
| 2017 Q2 | 990.23 Thousand CAD | -1.0% |
| 2017 FY | 3.22 Million CAD | 341.8% |
| 2016 Q3 | 117.78 Thousand CAD | -39.5% |
| 2016 Q2 | 194.69 Thousand CAD | -16.84% |
| 2016 FY | 729.94 Thousand CAD | 140.51% |
| 2016 Q1 | 234.13 Thousand CAD | -22.86% |
| 2016 Q4 | 729.94 Thousand CAD | 519.72% |
| 2015 Q1 | 161.64 Thousand CAD | -41.11% |
| 2015 Q3 | 151.36 Thousand CAD | 181.86% |
| 2015 Q4 | 303.5 Thousand CAD | 100.52% |
| 2015 FY | 303.5 Thousand CAD | 10.57% |
| 2015 Q2 | 53.7 Thousand CAD | -66.78% |
| 2014 Q4 | 274.49 Thousand CAD | -85.46% |
| 2014 Q1 | 1.7 Million CAD | 6.99% |
| 2014 FY | 274.49 Thousand CAD | -82.81% |
| 2014 Q3 | 1.88 Million CAD | 10.22% |
| 2014 Q2 | 1.71 Million CAD | 0.26% |
| 2013 Q2 | 1.64 Million CAD | -1.56% |
| 2013 FY | 1.59 Million CAD | -5.58% |
| 2013 Q4 | 1.59 Million CAD | -6.0% |
| 2013 Q3 | 1.69 Million CAD | 3.15% |
| 2013 Q1 | 1.67 Million CAD | -1.09% |
| 2012 Q4 | 1.69 Million CAD | -77.89% |
| 2012 Q3 | 7.64 Million CAD | -0.18% |
| 2012 Q1 | 7.74 Million CAD | -2.52% |
| 2012 FY | 1.69 Million CAD | -78.72% |
| 2012 Q2 | 7.66 Million CAD | -1.11% |
| 2011 Q2 | 3.34 Million CAD | -5.5% |
| 2011 Q3 | 9.65 Million CAD | 188.19% |
| 2011 Q4 | 7.94 Million CAD | -17.62% |
| 2011 FY | 7.94 Million CAD | 168.62% |
| 2011 Q1 | 3.54 Million CAD | 19.74% |
| 2010 Q4 | 2.95 Million CAD | -13.07% |
| 2010 Q1 | 3.58 Million CAD | -14.48% |
| 2010 Q3 | 3.4 Million CAD | -2.96% |
| 2010 FY | 2.95 Million CAD | -29.42% |
| 2010 Q2 | 3.5 Million CAD | -2.15% |
| 2009 Q3 | 3.95 Million CAD | 42.34% |
| 2009 Q4 | 4.19 Million CAD | 5.98% |
| 2009 FY | 4.19 Million CAD | 118.75% |
| 2009 Q1 | 2.54 Million CAD | 32.78% |
| 2009 Q2 | 2.77 Million CAD | 9.21% |
| 2008 Q2 | 1.98 Million CAD | 27.15% |
| 2008 Q4 | 1.91 Million CAD | -10.18% |
| 2008 FY | 1.91 Million CAD | 18.68% |
| 2008 Q3 | 2.13 Million CAD | 7.53% |
| 2008 Q1 | 1.56 Million CAD | -3.37% |
| 2007 Q4 | 1.61 Million CAD | -3.63% |
| 2007 Q2 | 1.77 Million CAD | 8.68% |
| 2007 FY | 1.61 Million CAD | 136.48% |
| 2007 Q1 | 1.63 Million CAD | 139.65% |
| 2007 Q3 | 1.67 Million CAD | -5.79% |
| 2006 Q3 | 769.84 Thousand CAD | 428.13% |
| 2006 Q2 | 145.76 Thousand CAD | 0.0% |
| 2006 Q4 | 682.95 Thousand CAD | -11.29% |
| 2006 FY | 682.95 Thousand CAD | 323.29% |
| 2005 FY | 161.34 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 4.19 Million CAD | 99.259% |
| Asep Medical Holdings Inc | 25.61 Million CAD | 99.879% |
| BetterLife Pharma Inc. | 324.74 Thousand CAD | 90.436% |
| BioVaxys Technology Corp. | 113.47 Thousand CAD | 72.63% |
| ChitogenX Inc. | 534 Thousand CAD | 94.184% |
| Rapid Dose Therapeutics Corp. | 1.88 Million CAD | 98.352% |
| Defence Therapeutics Inc. | 477.74 Thousand CAD | 93.499% |
| Entheon Biomedical Corp. | 401.07 Thousand CAD | 92.256% |
| Gemina Laboratories Ltd. | 1.45 Million CAD | 97.867% |
| Glow Lifetech Corp. | 1.91 Million CAD | 98.376% |
| Lexston Life Sciences Corp. | 750.94 Thousand CAD | 95.864% |
| Pharmala Biotech Holdings Inc. | 2.41 Million CAD | 98.713% |
| Doseology Sciences Inc. | 1.1 Million CAD | 97.182% |
| MYND Life Sciences Inc. | 797.54 Thousand CAD | 96.106% |
| PharmaTher Holdings Ltd. | 2.58 Million CAD | 98.801% |
| PreveCeutical Medical Inc. | 181.51 Thousand CAD | 82.889% |
| Telescope Innovations Corp. | 3.02 Million CAD | 98.973% |